Peoples Hospital of Quanzhou
Peoples Hospital of Quanzhou
Lin C.,Fujian Medical University |
Chen X.,Fujian Medical University |
Li M.,Fujian Provincial Cancer Hospital |
Liu J.,Fujian Medical University |
And 6 more authors.
Clinical Lung Cancer | Year: 2015
Background The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-L1 expression in patients with the subtype of NSCLC carrying EGFR mutations remain limited. Materials and Methods Immunohistochemistry was performed to evaluate the expression of PD-1, PD-L1, and CD4+ and CD8+ tumor-infiltrating T lymphocytes (TILs). Results In a cohort of 56 patients, PD-L1 and PD-1 was positive in 53.6% and 32.1% of tumor specimens, respectively. PD-L1+ patients had a significantly greater disease-control rate (P =.004), in association with longer progression-free survival (P =.001) after EGFR-tyrosine kinase inhibitor (TKI) therapy and overall survival (P =.004), and no correlation between PD-1 positivity and clinical outcomes was observed. PD-L1 expression was not significantly associated with either clinicopathologic features or TILs. Conclusions These findings suggest that this subtype of EGFR mutation-positive NSCLC is highly eligible for PD-1/PD-L1 immunotherapy. PD-L1 might represent a favorable biomarker candidate for the response to EGFR-TKIs and outcomes of these patients with NSCLC. © 2015 Elsevier Inc.
Wang Q.,Wenzhou Medical College |
Wang Q.,Key Laboratory of Vision Science |
Savini G.,Gb Bietti Eye Foundation Irccs |
Hoffer K.J.,University of California at Los Angeles |
And 9 more authors.
PLoS ONE | Year: 2012
Purpose: To comprehensively assess the precision and agreement of anterior corneal power measurements using 8 different devices. Methods: Thirty-five eyes from 35 healthy subjects were included in the prospective study. In the first session, a single examiner performed on each subject randomly measurements with the RC-5000 (Tomey Corp., Japan), KR-8000 (Topcon, Japan), IOLMaster (Carl Zeiss Meditec, Germany), E300 (Medmont International, Australia), Allegro Topolyzer (Wavelight AG, Germany), Vista (EyeSys, TX), Pentacam (Oculus, Germany) and Sirius (CSO, Italy). Measurements were repeated in the second session (1 to 2 weeks later). Repeatability and reproducibility of corneal power measurements were assessed based on the intrasession and intersession within-subject standard deviation (Sw), repeatability (2.77Sw), coefficient of variation (COV), and intraclass correlation coefficient (ICC). Agreement was evaluated by 95% limits of agreement (LoA). Results: All devices demonstrated high repeatability and reproducibility of the keratometric values (2.77Sw<0.36D, COV<0.3%, ICC>0.98). Repeated-measures analysis of variance with Bonferroni post test showed statistically significant differences (P<0.01) among mean keratometric values of most instruments; the largest differences were observed between the EyeSys Vista and Medmont E300. Good agreement (i.e., 95%LoA within ±0.5D) was found between most instruments for flat, steep and mean keratometry, except for EyeSys and Medmont. Repeatability and reproducibility of vectors J0 and J45 was good, as the ICCs were higher than 0.9, except J45 of Medmont and Pentacam. For the 95% LoAs of J0 and J45, they were all ≤ ±0.31 among any two paired devices. Conclusions: The 8 devices showed excellent repeatability and reproducibility. The results obtained using the RC-5000, KR-8000, IOLMaster, Allegro Topolyzer, Pentacam and Sirius were comparable, suggesting that they could be used interchangeably in most clinical settings. Caution is warranted with the measurements of the EyeSys Vista and Medmont E300, which should not be used interchangeably with other devices due to lower agreement. Trial Registration: ClinicalTrials.gov NCT01587287. © 2012 Wang et al.
Hu X.,Sun Yat Sen University |
Bao Y.,Sun Yat Sen University |
Zhang L.,Sun Yat Sen University |
Guo Y.,Sun Yat Sen University |
And 6 more authors.
Cancer | Year: 2012
BACKGROUND: Controversies exist with regard to thoracic radiotherapy volumes for limited-stage small cell lung cancer (SCLC). This study compared locoregional progression and overall survival between limited-stage SCLC patients who received thoracic radiotherapy to different target volumes after induction chemotherapy. METHODS: Chemotherapy consisted of 6 cycles of etoposide and cisplatin. After 2 cycles of etoposide and cisplatin, patients were randomly assigned to receive thoracic radiotherapy to either the postchemotherapy or prechemotherapy tumor extent as study arm or control. Elective nodal irradiation was omitted for both arms. Forty-five Gy/30Fx/19 days thoracic radiotherapy was administered concurrently with cycle 3 chemotherapy. Prophylactic cranial irradiation was administered to patients who achieved complete remission. An interim analysis was planned when the first 80 patients had been followed for at least 6 months, for consideration of potential inferiority in the study arm. RESULTS: Forty-two and 43 patients were randomly assigned to a study arm and a control, respectively. The local recurrence rates were 31.6% (12 of 38) and 28.6% (12 of 42), respectively (P =.81). The isolated nodal failure rates were 2.6% (1 of 38) and 2.4% (1 of 42), respectively (P = 1.00). All isolated nodal failure sites were in the ipsilateral supraclavicular fossa. Mediastinal N3 was the only factor to predict isolated nodal failure (P =.004; odds ratio [OR], 29.33; 95% CI, 2.94-292.38). One-year and 3-year overall survival rates were 80.6%, 36.2%, and 78.9%, 36.4%, respectively (P =.54). CONCLUSIONS: Preliminary results indicated that irradiated postchemotherapy tumor extent and omitted elective nodal irradiation did not decrease locoregional control in the study arm, and the overall survival difference was not statistically significant between the 2 arms. Further investigation is warranted. Copyright © 2011 American Cancer Society.
PubMed | The 476th Hospital of Peoples Liberation Army, Fujian Medical University and Peoples Hospital of Quanzhou
Type: Journal Article | Journal: BMJ open | Year: 2016
Whether adding percutaneous transluminal angioplasty and stenting (PTAS) to background medical treatment is effective for decreasing the incidence of stroke or death in patients with symptomatic intracranial atherosclerosis (ICAS) is still controversial. We perform a randomised controlled trial to examine the effectiveness and safety of an improved PTAS procedure for patients with ICAS.A randomised controlled trial will be conducted in three hospitals in China. Eligible patients with ICAS will be randomly assigned to receive medication treatment (MT) plus PTAS or MT alone. The MT will be initiated immediately after randomisation, while the PTAS will be performed when patients report relief of alarm symptoms defined as sudden weakness or numbness. All patients will be followed up at 30days, 3 and 12months after randomisation. The primary end point will be the incidence of stroke or death at 30days after randomisation. Secondary outcomes will be the incidence of ischaemic stroke in the territory of stenosis arteries, the incidence of in-stent restenosis, the Chinese version of the modied Rankin Scale and the Chinese version of the Stroke-Specific Quality of Life (CSQoL).The study protocol is approved by institutional review boards in participating hospitals (reference number FZ20160003, 180PLA20160101 and 476PLA2016007). The results of this study will be disseminated to patients, physicians and policymakers through publication in a peer-reviewed journal or presentations in conferences. It is anticipated that the results of this study will improve the quality of the current PTAS procedure and guide clinical decision-making for patients with ICAS.NCT02689037.
Pan X.-N.,Peoples Hospital of Quanzhou |
Zheng L.-Q.,Peoples Hospital of Quanzhou |
Lai X.-H.,Peoples Hospital of Quanzhou
World Journal of Gastroenterology | Year: 2014
AIM: To assess the efficacy and safety of bone marrow-derived mesenchymal stem cell (BM-MSC) in the treatment of decompensated liver cirrhosis. METHODS: The search terms "bone marrow stem cell" "chronic liver disease" "transfusion" and "injection" were used in the Cochrane Library, Med-Line (Pub-Med) and Embase without any limitations with respect to publication date or language. Journals were also hand-searched and experts in the field were contacted. The studies which used BM-MSC in the treatment of any chronic liver disease were included. Comprehensive Review Manager and Meta-Analyst software were used for statistical analysis. Publication bias was evaluated using Begg's test. RESULTS: Out of 78 studies identified, five studies were included in the final analysis. The studies were conducted in China, Iran, Egypt and Brazil. Analysis of pooled data of two controlled studies by Review Manager showed that the mean decline in scores for the model for end-stage liver disease (MELD) was -1.23 [95%CI: -2.45-(-0.01)], -1.87 [95%CI: -3.16-(-0.58)], -2.01 [95%CI: -3.35-(-0.68)] at 2, 4 and 24 wk, respectively after transfusion. Meta-analysis of the 5 studies showed that the mean improvement in albumin levels was -0.28, 2.60, 5.28, 4.39 g/L at the end of 8, 16, 24, and 48 wk, respectively, after transfusion. MELD scores, alanine aminotransferase, total bilirubin levels and prothrombin times improved to some extent. BM-MSC injections resulted in no serious adverse events or complications. CONCLUSION: BM-MSC infusion in the treatment of decompensated liver cirrhosis improved liver function. At the end of year 1, there were no serious side effects or complications. © 2014 Baishideng Publishing Group Inc. All rights reserved.
Wei M.-J.,Peoples Hospital of Quanzhou |
Pan X.-N.,Peoples Hospital of Quanzhou |
Wei K.-P.,Peoples Hospital of Quanzhou |
Li X.-H.,Peoples Hospital of Quanzhou |
And 5 more authors.
International Immunopharmacology | Year: 2015
Abstract Dendritic cells (DCs) are multifunctional cells that initiate adaptive immune responses. Patients with chronic hepatitis B virus (HBV) infection have reduced numbers of DCs which may be functionally impaired, a defect that may contribute to viral persistence. Autologous DC-based immunotherapy is considered to be a treatment option for chronic HBV infection (CHB). We evaluated the therapeutic efficacy of HBV-pulsed DCs in combination with the antiviral drug entecavir in patients with CHB. Eighty patients were divided into four groups: HBV-pulsed DCs only, HBV-pulsed DCs plus entecavir, entecavir only, and an untreated control group. Patients on combination therapy exhibited greater antiviral responses than patients on either monotherapy. The combination of HBV-pulsed DCs and entecavir resulted in the largest reduction in serum viral DNA levels and the highest percentage of virologic response. In addition, combination therapy resulted in viral e antigen (HBeAg) loss and seroconversion. These results suggest that the combination of HBV-pulsed autologous DCs and entecavir could be therapeutically advantageous for patients with CHB. © 2015 Elsevier B.V.
He J.P.,Peoples Hospital of Quanzhou
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery | Year: 2012
To observe the microstructural changes of olfactory mucosa in rat model with acute rhinosinusitis leading to olfactory dysfunction, and to provide foundation for further exploration of corresponding mechanism. On the basis of prior successfully established rat model of acute rhinosinusitis through inoculation with Streptococcus pneumoniae and with the help of merocel strips, one hundred healthy SD rats were randomly divided into experimental group (80) and control group (20). After inoculation, every 20 rats in the experimental groups were sacrificed in first week, second week, third week and fourth week respectively; and all rats in the control group were sacrificed in first week after the inoculation. Before the rats were sacrificed, the method called "buffed food pellet test, BFPT" was adopted, which was advanced by professor Nathan, to measure the rats' olfaction,and the time of every rat spending in finding out the food pellet was recorded and analyzed. BFPT showed that the rats in experimental group spent (402.9 ± 9.3), (453.7 ± 7.3), (351.9 ± 8.9), (278.7 ± 8.1) s respectively in searching the food pellet, which were more than the rats in the control group [(178.3 ± 6.6) s]. Then the olfactory mucosa was collected under anatomic microscope from all the rats to make frozen section and detect the changes of mature olfactory receptor neurons (ORN) and olfactory ensheathing cells (OEC) by immunofluorescence technique. The reduction of ORN in various degrees could be detected in the tissue samples of olfactory mucosa among all the rats in experimental group, with a tendency to become thinner in the thickness of epithelial lamina during the inflammation developing course. This kind of pathology was most marked in the second week and it gradually developed into the stage showing the lesion being the feeblest in the forth week following the beginning of modeling. Although the number of olfactory ensheathing cells appeared reduction in the first week following the beginning of modeling as well,it came to increase from the second week before olfactory receptor neurons and almost completely recovered to normal in the fourth week. In addition, some olfactory ensheathing cells could be detected in the tissue samples of olfactory mucosa among all the rats in experimental group. Both mature olfactory sensory neurons and olfactory ensheathing cells appeared to reduction when sinonasal mucosa taken place acute rhinosinusitis. But the number of olfactory ensheathing cells increased faster than olfactory sensory neurons. In addition, some olfactory ensheathing cells could be detected in the olfactory epithelium.
Zhuang W.,Peoples Hospital of Quanzhou |
Weng W.,Peoples Hospital of Quanzhou
Shanghai kou qiang yi xue = Shanghai journal of stomatology | Year: 2011
PURPOSE: To study the influence of heat treatment on retention force of magnetic attachments.METHODS: Three groups of magnetic attachments (including 10 Magfit EX 400W, 10 Magfit EX 600W, 10 Magfit EX 800W) were fixed on universal test machine respectively. The retention force of each attachment was measured. After heat treatment, their retention force was measured again. The difference of retention force before and after heat treatment was compared using SPSS11.0 software package.RESULTS: The average retention force of magnetic attachments (Magfit EX 400W) was (1.58±0.12)N before heat treatment and (1.64±0.11)N after heat treatment. The average retention force of magnetic attachments (Magfit EX 600W) was (2.67±0.19)N before heat treatment and (2.65±0.14)N after heat treatment.The average retention force of magnetic attachments (Magfit EX 800W) was (3.02±0.25)N before heat treatment and (3.02±0.24)N after heat treatment. The retention force of magnetic attachments had no significant change after heat treatment (P>0.05).CONCLUSION: The magnetic attachments can be treated by waterbath heart treatment in the clinic without significant change of their retention force.
Xu Z.-J.,Peoples Hospital of Quanzhou |
Zheng L.-Q.,Peoples Hospital of Quanzhou |
Pan X.-N.,Peoples Hospital of Quanzhou
World Journal of Gastroenterology | Year: 2015
Ligation of splenic artery (LSA) is used for the treatment of liver cirrhosis with hypersplenism. However, hypersplenism is not significantly improved following LSA treatment in some cases, and there are few reports of retreatment of hypersplenism after LSA. We report the case of a 47-year-old man with liver cirrhosis and hypersplenism who underwent LSA treatment, but did not significantly improve. Laboratory tests revealed severe leukocytopenia and thrombocytopenia. Celiac computed tomography arteriogram and digital subtraction angiography revealed two compensatory arteries connected to the hilar splenic artery from the left gastro-epiploic artery and from the dorsal pancreatic artery. Partial splenic embolization (PSE) was performed through the compensatory arteries. As a result, the patient achieved partial splenic ischemic infarction, and white blood cell and platelet counts rose and remained in the normal range. PSE is an effective therapeutic modality for the retreatment of hypersplenism when other modalities have failed. © The Author(s) 2015.
PubMed | Peoples Hospital of Quanzhou
Type: Journal Article | Journal: Cell biochemistry and biophysics | Year: 2016
The objective of this study was to follow-up long term (5-12 years) patients with total hip arthroplasty with the collum femoris preserving prosthesis to evaluate clinical outcome and potential complications. Forty-six of 152 patients who underwent this procedure between September 2000 and September 2012 were followed up. The average follow-up time was 7.6 years, and assessed were radiographs, Harris score, limb length, hip function, and complications. Six patients had perioperative complications including five cases of femoral shaft fracture and one case of dislocation 1 week after the operation. No infections of the surgical site, no deep venous thrombosis or pulmonary embolism were observed. The last recorded Harris hip score improved from a preoperative average of 41.2 (range 17-60) to an average of 82.3 (74-96), with the score >80 in 38 patients, 70-80 in six patients, and <70 in two patients. Radiolucent lines were found on radiographs in two patients with acetabular prosthesis and one patient with femoral prosthesis. The remainder of patients had satisfactory positions of acetabular and femoral stem prostheses with no loosening or subsidence, and a good condition of femoral neck. Total hip arthroplasty with the collum femoris preserving prosthesis is a good option for younger patients who need prosthesis revision. This arthroplasty achieves satisfactory long-term effectiveness.